Analysis of the central memory T cells (TCM, CD4+CD44+ CD122+) in the spleens in the primary CT26 tumour-bearing mice on day 11 (1 week after the third (last) treatment) showed that the spleens of the mice treated with IPLD had a significantly increased population of TCM compared with those treated with PBS, IOXL, or PLD (Fig. 7d; Supplementary Fig. 80). The gene discussed is CD4; the disease is neoplasm.